About

Michael O’Rourke is Chief Executive Officer and a Board Director of Re-Vana Therapeutics. He is also specialised ophthalmic pharma consultant with more than three decades’ expertise in pharmaceutical, drug delivery and medical device strategies. In 2009 he founded Scotia Vision Consultants advising ophthalmic companies on commercialisation and product development with a focus on anterior and posterior ocular drug delivery. Previously he’s worked for 3M, Pfizer, Alza, Chiron Vision, Bausch + Lomb and GrayBug.

Contributions

EXPERT VIEW

SUSTAINED RELEASE OCULAR THERAPEUTICS

Michael O’Rourke gives an overview of the current state of the ophthalmics market, going into greater detail on the opportunities offered in the area of sustained-release technologies and therapies.

More contributions

EXPERT VIEW

SUSTAINED-RELEASE OCULAR DELIVERY TECHNOLOGIES

Michael O'Rourke discusses the advances in the development and launching of sustained-release ocular drug delivery systems seen in recent years.

COMPANY SHOWCASE: GRAYBUG

GrayBug is advancing ophthalmic therapeutics through a continuum of polymerbased drug delivery platforms and innovative products offering sustained competitive advantage.